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Abstract
Background: Human Papillomavirus-32 (HPV-32) has traditionally been associated with focal-
epithelial-hyperplasia (FEH). It is also present in 58% of oral warts of HIV-positive individuals whose
prevalence is increasing. Current methods for the detection of HPV-32 are labor-intensive and
insensitive so the goal of this work was to develop a highly sensitive and easy to use specific
polymerase chain reaction (PCR) assay.
Materials and methods: An HPV-32 L1 specific PCR assay was developed and optimized. The
sensitivity and specificity was compared to previous assays utilized for detection (PGMY and MY09/
11 PCR with dot blot hybridization) using cloned HPV-32 L1, the closely related HPV-42 L1 as well
as clinical samples (oral swabs and fluids from 89 HIV-positive subjects).
Results: The HPV-32 specific PCR assay showed improved sensitivity to 5 copies of HPV-32 as
compared to the PGMY PCR, MY09/11 PCR and dot blot which had a limit of detection of
approximately 3,000 copies. Using the HPV-32 dot blot hybridization assay as the gold standard,
the HPV-32 specific PCR assay has a sensitivity of 95.8% and 88.9% by sample and subject,
respectively, and specificity was 87.8% and 58.8% by sample and subject, respectively. The low
sensitivity is due to the HPV-32 specific PCR assays ability to detect more HPV-32 positive samples
and may be the new gold standard.
Conclusion: Due to the ease, sensitivity, and specificity the HPV-32 specific PCR assay is superior
to previous assays and is ideal for detection of HPV-32 in large cohorts. This assay provides an
excellent tool to study the natural history of HPV-32 infection and the development of oral warts.
Background
Human Papillomavirus (HPV) is the most common sexu-
ally transmitted viral infection in the world with greater
than 100 genotypes described to date [1-3]. High risk HPV
genotypes (HPV-16 and -18 for example) are associated
with human malignancy including as much as 95% of cer-
vical cancers and up to 35% of oral malignancies. The low
risk HPV types, for example HPV-6 and -11, are the etio-
logic agent of benign hyperproliferations (warts) with can
occur in the genital tract or oral cavity and are a significant
health problem.
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HPV-32 has only been well described in the oral cavity. In
a study of 67 high-risk individuals composed of more
than 85% HIV-positive individuals HPV-32 was the most
prevalent type detected in oral lesions (40%)[4]. It was
detected in 30% of warts, 67% of FEH, 50% of fibroma,
and 20% of focal keratosis. This study utilized a complex
series of PCR assays designed to detect a broad spectrum
of HPV types including genital, oral, and cutaneous types
found in humans as well as animal. This was accom-
plished utilizing a series of primers for highly conserved
sequences in the L1 open reading frame and radiolabeled
probes for Southern blot analysis. In a New Orleans HIV-
positive cohort 58% of oral wart biopsies contain HPV-32
DNA with HPV-6, -7, -11, -16, -18, and -73 also detected
[5]. HPV-32 was detected by amplification with degener-
ate MY09/11 primers designed to detect genital HPV types
followed by direct sequencing. In the advent of wide-
spread use of highly active anti-retroviral therapy
(HAART) an increase in oral warts has been observed
while decreases in other types of oral lesions have been
noted over the same time period [6-8]. This coupled with
the fact that most oral warts in HIV-positive individuals
are due to HPV-32 makes further study into the natural
history of these HPV-32 infections warranted.
The prevalence rate of HPV-32 infection in the oral cavity
of HIV-positive and HPV-negative populations without
obvious lesions has not been well studied. One study did
show a prevalence rate of 1.6% in a cohort of normal,
healthy individuals from South Africa [9] utilizing MY09/
11 degenerate primers followed by direct sequencing.
Using the same primers in conjunctions with dot-blot
hybridization, Cameron and Hagensee showed a preva-
lence rate of 5.7% in the New Orleans HIV-positive cohort
[5]. This assay was shown to be rather insensitive and able
to only detect 2.5 picograms of cloned HPV-32 DNA [5].
The New Orleans and South African studies described
above used PCR assays utilizing primers designed to
detect genital HPV types (MY09/11 and PGMY primer
sets). Although these methods are capable of detecting
HPV-32, the sensitivity has not been determined but is
expected to be low. With an increase in oral HPV infection
and disease in HIV-positive individuals on HAART, and
with HPV-32 being prevalent in the oral cavity, improved
methods to detect HPV-32 are warranted. This study
describes the development of a type-specific PCR-based
assay to detect HPV-32 for the application in a natural his-
tory study of HPV-32 and oral wart progression.
Results
Sensitivity of the Current HPV Detection Assays
Previous work in our laboratory [5] has noted that both
the PGMY and MY09/11 primer sets will amplify HPV-32
using either cloned HPV-32 DNA or DNA isolated from
oral warts determined to be homologous to HPV-32. After
amplification, the identity of the HPV types amplified was
confirmed to be HPV-32 by dot-blot hybridization using
specific HPV-32 probes. The sensitivity of both PCR
amplification step and dot blot was never formally tested.
The sensitivity of these primer pairs was tested by attempt-
ing to amplify serial dilutions of the cloned HPV-32 L1
gene (pMJ32L1). Three separate 10× dilution schemes
were generated: 500,000 → 5; 300,000 → 3; and 100,000
→ 1. These dilution series were each tested three times and
each dilution scheme was run in duplicate for a total of 6
experiments. These two assays showed a comparable sen-
sitivity with the ability to detect approximately 3,000 cop-
ies of HPV-32 L1 gene (Figure 1A, B). Hybridization steps
can often increase sensitivity and this was tested utilizing
the amplicons from the cloned HPV-32 L1 gene dilution
Sensitivity of the PGMY09/11 (1A), MY09/11 (1B), and HPV- 32 Specific (1C) PCRs were tested using dilutions of plasmid  (pMJ32L1) containing HPV-32 L1 gene Figure 1
Sensitivity of the PGMY09/11 (1A), MY09/11 (1B), 
and HPV-32 Specific (1C) PCRs were tested using 
dilutions of plasmid (pMJ32L1) containing HPV-32 L1 
gene. Each assay was tested on a dilutions scheme starting at 
500,000 down to 1 copy. Figure contains a representative gel 
from 6 experiments (three separate dilutions done in dupli-
cate). The sensitivity of both the PGMY09/11 and MY09/11 
PCR assays were shown to be approximately 3,000 copies of 
HPV-32 L1. The HPV-32 Specific PCR consistently detected 
5 copies of HPV-32 L1.Virology Journal 2009, 6:90 http://www.virologyj.com/content/6/1/90
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series that were amplified with the MY09/11 primers. The
addition of the dot blot hybridization step using HPV-32
specific probes did not affect the overall sensitivity of the
assay (Figure 2). The Roche reverse line blot system does
not utilize an HPV-32 specific probe in the line blot assay
so sensitivity of this genotyping system could not be done.
Due to this relative lack of sensitivity for both amplifica-
tion systems, a HPV-32 type specific PCR assay was devel-
oped.
HPV-32 Specific PCR Development
PCR primers were designed using PrimerSelect in the
LaserGene 6 DNA and Protein Analysis Software (DNAS-
TAR, Inc., Madison, WI) to generate a 100–200 bp ampli-
con and have no cross-reactivity with other known DNA
sequences. The HPV-32 specific primers (HPV-32 Det For
and Rev, table 1) generate a 134 bp amplicon and have no
potential cross-reactivity with human genomic DNA and
limited cross-reactivity with known HPV types as tested
utilizing NCBI's Basic Local Alignment Search Tool
(BLAST, http://www.ncbi.nlm.nih.gov/BLAST/). The
assay was optimized by varying the magnesium concen-
tration and annealing temperature (data not shown). Due
to the primers need for a precise magnesium concentra-
tion for optimal sensitivity a commercial master mix
could not be utilized. To limit variation in PCR reactions
and pipeting errors a master mix for each PCR was pro-
duced and aliquoted appropriately
Sensitivity
Serial dilutions of known quantities of cloned HPV-32 L1
(pMJ32L1) was used to determine the sensitivity of the
HPV-32 specific assay. These experiments showed that the
HPV-32 specific PCR was reproducibly sensitive down to
5 copies of the HPV-32 L1 gene (Figure 1C).
Specificity
Specificity of any HPV PCR assay is of significant concern
because genotypes are defined by only a 10% difference in
the nucleotide sequence of their E6, E7, and L1 open read-
ing frames (ORFs). For this reason a number of experi-
ments were performed to test the assay's specificity. First,
because of the potential of cross-priming, the primer's
sequences were compared to other HPV types. This analy-
sis noted that the HPV-42 L1 gene was the most closely
related to HPV-32. HPV-42 has no mismatches in the for-
ward primer and only four mismatches in the reverse
primer. Purified and quantified pMJ42L1 (107 billion cop-
ies) was used as the template for four separate PCR reac-
tions and in all cases, HPV-42L1 gene was not amplified,
while only 5 copies of the HPV-32 L1 gene was detected
(data not shown). Next, using clinical material, six archi-
val samples that had previously tested positive for HPV-42
by the Roche reverse line blot assay were identified and
retested positive for HPV-42. These six samples were then
subjected to PCR amplification using the HPV-32 L1 spe-
cific primers. Two of the six samples amplified. The assay
volume was quadrupled (100 μL), reamplified, and the
resultant amplicons sequenced. They were found to have
the best homology (85.4% and 98.7%) with HPV-32. This
implied that this clinical sample contained both HPV-32
and HPV-42. Finally, clinical samples (45 subjects) that
were previously found to contain HPV types (number): 6
(n = 5), 16 (8), 18 (2), 26 (10), 33 (1), 35 (2), 39 (19), 45
(21), 51 (1), 53 (2), 55 (17), 58 (5), 59 (13), 62 (6), 66
(3), 69 (1), MM4 (12), MM7/83 (24), MM8 (13), and
MM9 (7) were amplified via the HPV-32 Specific PCR and
were found to be negative.
Reproducibility
Subjects (n = 89) were enrolled in a study on oral HPV
infection from the New Orleans HOP clinic (see Materials
and Methods). Reproducibility of the assay was assessed
by retesting 14 patients (111 samples) with 57 of these
samples positive for HPV-32. Overall, 94.6% of the sam-
ples were reproducible. Gingiva, tongue, sublingual, and
saliva sites each had a single sample not reproduce, while
the hard palate site had two samples not reproduce
(table 2).
Comparison of the HPV-32 Specific PCR to the Dot Blot 
Assay
The optimized HPV-32 Specific PCR assay was compared
to the laboratory's previous gold standard assay for detect-
Sensitivity of the HPV-32 dot blot assay Figure 2
Sensitivity of the HPV-32 dot blot assay. (A) Serial dilu-
tion of pMJ32L1 detected via MY09/11 PCR. (B) The hybridi-
zation step did not increase the sensitivity of the assay.Virology Journal 2009, 6:90 http://www.virologyj.com/content/6/1/90
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ing HPV-32: PCR amplification using MY09/11 primers
followed by dot blot hybridization using HPV-32 specific
probes. A group of 663 samples from 89 HIV-positive sub-
jects who were screened positive for HPV DNA using
PGMY primers but could not be genotyped using the
reverse line blot assay. The integrity of these stored sam-
ples were verified by the detection of the β-globin gene.
The HPV-32 dot blot assay detected HPV-32 in twenty-
four oral samples (3.6%) from nine subjects (10%). All
but one (23) of these HPV-32 positive samples were pos-
itive by the HPV-32 specific PCR (Table 3). An additional
78 HPV-32 positive samples were identified that were neg-
ative by the dot blot assay. The HPV-32 type specific PCR
assay has a sensitivity of 95.8% and a specificity of 87.8%
with a kappa of 0.32 ± 0.029 as compared to the HPV-32
dot blot assay. When analyzed according to subjects, one
subject was not detected with the HPV-32 specific assay
which was detected by the dot blot assay. In contrast, 33
subjects (37%) were positive by the HPV-32 specific assay
and negative via the HPV-32 dot blot (kappa of 0.18 ±
0.068; sensitivity of 88.9%; specificity of 58.8%, Table 4).
The new HPV-32 specific PCR system targeting the L1
gene demonstrated significantly increased sensitivity as
compared to the laboratory's previous gold standard of
MY09/11 amplification and dot blot hybridization. This
could be due to the robustness of this new assay or due to
laboratory contamination. Review of the PCR runs noted
no false positive in no template controls making lab con-
tamination less likely. A verification assay was developed
which targeted the HPV-32 E6/E7 region. In a group of 45
oral samples from 5 patients, the E6E7 PCR assay con-
firmed 22 of the previously identified HPV-32 positive
samples by the L1 assay. The E6E7 assay detected a posi-
tive sample among the 23 believed to be negative by the
L1 assay. The agreement was almost perfect with a kappa
of 0.96 ± 0.148. It is concluded that the increased sensitiv-
ity seen is due to the robustness of the HPV-32 L1 PCR
assay implying that this assay is the new gold standard.
Discussion
Previous studies in the Hagensee laboratory have shown
HPV-32 to be the most common HPV type found in oral
warts in HIV positive individuals[5]. The natural history
of oral HPV-32 infection has not been extensively studied.
In order to accurately characterize the natural history of
this infection, a highly sensitive, rapid, inexpensive, and
specific assay is required. The current method of detection
of HPV-32 requires PCR amplification and a blot/probe
hybridization which is labor-intensive and expensive. Uti-
lizing purified pMJ32L1, the sensitivity for two gold-
standard HPV PCR assays, PGMY09/11 and MY09/11
PCRs, was shown to be approximately 3,000 copies. In
contrast, the PGMY09/11 Reverse Line Blot System can
detect 10 to 1,000 copies of most of the genotypes found
on the blot [10]. Utilizing an HPV-32 dot blot assay did
not improve sensitivity, thus a HPV-32 type specific PCR
assay was developed and optimized.
Sensitivity, specificity, and reproducibility are critical to
the development of any new assay. The sensitivity of the
HPV-32 assay was determined using purified HPV-32
DNA and was determined to be 5 copies of cloned DNA.
This was significantly more sensitive than both the PGMY
and MY09/11 based PCR amplification assays (3,000 cop-
ies). The superior sensitivity was confirmed with clinical
samples whereby 33 subjects with a total of 78 samples
that were negative by current detection assays were found
Table 1: Summary of the HPV detection assays.
Name Primers HPV Amplify Genotype
PGMY PGMY09/11 +/- Most Genital Genotypes N.A.
Reverse Line Blot Assay PGMY09/11 +/- N.A. 27 Genital Genotypes
HPV-32 Dot Blot System MY09/11 +/- Most Genital Genotypes HPV-32
HPV-32 Specific PCR Assay HPV-32 Det For/Rev +/- HPV-32 HPV-32
Table 2: Reproducibility of the HPV-32 Specific PCR with 
samples from 14 subjects
Site Reproduced/Total Percent Reproduced
Labial 13/13 100
Buccal Mucosa 14/14 100
Gingiva 11/12 91.7
Tongue 13/14 92.9
Sublingual 11/12 91.7
Hard Palate 11/13 84.6
Tonsils 12/12 100
Saliva 11/12 91.7
Gargle 9/9 100
Table 3: Comparison of the HPV-32 Specific PCR and MY09/11 
HPV-32 dot blot detection methods by samples
HPV-32 PCR
+-
HPV-32 Dot Blot + 23 1
- 78 561Virology Journal 2009, 6:90 http://www.virologyj.com/content/6/1/90
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to be positive for HPV-32 by the HPV-32 specific PCR
assay. This increased sensitivity was confirmed by a sec-
ond assay which detected a different gene in HPV-32. This
sensitivity increase is predictable as it has been observed
in genital HPV prevalence studies. A healthy non-immu-
nosuppressed female population has genital HPV-16
infection rates varying from 2.0–5.4% using consensus/
degenerate primers [11-13] while type specific primers
detect higher rates of 9.4–9.7% [11-15].
An HPV genotype is defined as a ≥ 10% difference in E6,
E7, and L1 open reading frame sequences. The specificity
was tested theoretically by genomic alignments, as well as
empirically and found to be excellent. Due to the higher
sensitivity of the HPV-32 specific PCR, this HPV type was
detected more readily in clinical samples; thereby, show-
ing lower specificity, sensitivity, and agreement (kappa
value) with the current detection methods. The issue of
cross-reactivity was tested utilizing the most closely
related DNA sequence known (HPV-42 L1) which has
only four mismatches within the primer regions. The
HPV-32 specific PCR did not amplify in the presence of >
107 copies of HPV-42 L1 thereby showing the stringent
specificity of the PCR. Clinical samples positive for HPV-
42 either did not have HPV-32 in them or were found to
be co-infected with HPV-32. There was no evidence of
cross-priming with the HPV-32 primers and amplification
from a HPV-42 DNA template.
The reproducibility of the assay was shown by the ability
to repeatedly detect HPV-32 in clinical samples. All oral
cavity sites sampled showed high reproducibility (> 92%)
with the exception of the hard palate (84.6%). The lower
rate of reproducibility of the hard palate may be due to a
low level of infection which would be at the level of detec-
tion of the HPV-32-specific PCR assay. This is supported
by the relatively lower rate of infection (10.1%) at the
hard palate and is also supported by the faint bands seen
in 5 out of the 6 discordant results implying low viral
loads.
Although this assay demonstrated increased sensitivity,
excellent specificity and reproducibility, it is not optimal.
Most modern PCR assays utilize a standardized universal
master mix to which the specific primers are added. How-
ever, this approach does not allow one to vary the magne-
sium concentration which was critical to the optimization
of the HPV-32 specific L1 assay in order to achieve the
maximum sensitivity. The current assay could also be
improved by the use of dUTP and addition of U-glucosi-
dase step which would degrade any pre-existing amplicon
DNA from previous amplification. This feature could fur-
ther limit any additional laboratory contamination.
In conclusion, the HPV-32 specific PCR assay has been
shown to have increased sensitivity, and excellent specifi-
city as compared to current assays. In addition, this assay
is highly reproducible and is less labor-intensive. This
makes the assay ideal to assess the natural history of HPV-
32 in the oral cavity.
Materials and methods
Cloning of HPV-32 and HPV-42 L1 Gene
HPV-32 and -42 L1 genes were cloned directionally into
pMJ601 (designated pMJ32L1 and pMJ42L1, respec-
tively), grown in E. coli, and extracted via a ProMega Min-
iPrep Kit according to their protocol. The DNA
concentration was quantified using a DU 530 Life Sci-
ences UV/Vis Spectrophotometer and confirmed by
Eppendorf BioPhotometer.
Patient Population
For the clinical samples utilized, subjects were enrolled in
the Medical Center of Louisiana at New Orleans
(MCLNO) HIV outpatient program (HOP) Clinic in New
Orleans, LA, from May 2002 to December 2003. One-
hundred-seventy subjects whose oral samples were previ-
ously tested for HPV DNA were utilized. Subjects gave
informed consent by a trained professional according to
the LSUHSC Institutional Review Board (IRB) and the
MCLNO HOP research committee accepted protocol. All
subjects were given a comprehensive exam for all oral
lesions by a health professional. In addition to the oral
samples, basic demographic information, peripheral
CD4+ T-cell count and HIV viral load was collected from
each subject as well as current HIV medications.
Sample Collection and Processing
Cells were collected from the buccal mucosa, labia, gin-
giva, tongue, sublingual surface, hard palate, and tonsils
by vigorously rubbing the surfaces with a sterile swab
(Puritan, Guilford, Maine). These sites were chosen for
their association with HPV associated lesions and head
and neck squamous cell carcinomas. The swabs were
stored in Specimen Transport Medium (DIGENE, Gaith-
ersburg, MD) at 4°C. Unstimulated expectorated saliva (5
mL) was collected in a 50 mL conical tube. Five milliliters
of sterile saline was gargled and expectorated into a 50 mL
conical tube. Both saliva and gargle samples were stored at
4°C as well. Saliva and gargle samples were processed
within 4 hours, and sample DNA extracted within 18
hours of collection.
Table 4: Comparison of the HPV-32 Specific PCR and MY09/11 
HPV-32 dot blot detection methods by subjects
HPV-32 PCR
+-
HPV-32 Dot Blot + 81
- 33 47Virology Journal 2009, 6:90 http://www.virologyj.com/content/6/1/90
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Saliva and gargle specimens were processed by homoge-
nizing the sample through an 18 gauge needle and
syringe. The specimen was then centrifuged at 1,260 × g
for 10 minutes. Supernatants were removed, and the cell
pellet was resuspended in 1 mL of sterile PBS and stored
at 4°C until extraction.
DNA from all samples was extracted using the QIAGEN
Blood Extraction Kit (Germany), according to the manu-
facturer's protocols. Extracted DNA was stored at -20°C
until HPV detection by PCR was performed.
HPV Genotyping
Reverse Line Blot System
HPV genotyping was done using the Roche HPV Reverse
Line Blot system according to the manufacturer's protocol
(Roche Molecular Systems, Inc., Alameda, California).
Briefly, multiplex PCR amplified a 448 bp sequence of the
L1 Gene and 268 bp sequence of β-Globin (housekeeping
gene) using biotinylated PGMY09/PGMY11 consensus/
degenerate primers and GH20/PCO4 primers, respec-
tively [10]. Thermocycling was done on a PCT-100 (MJ
Research, Inc Waltham, MA) as follows: 50°C for 2 min-
utes, 95°C for 9 minutes, 40 cycles of 95°C for 1 minute,
55°C for 1 minute, and 72°C for 1 minute, extension at
72°C for 5 minutes, followed by a 15°C hold. The ampli-
cons were visualized on a 2.0% agarose gel with 0.5 μg/
mL ethidium bromide. The PGMY primer amplification
will detect most genital HPV types as well as HPV-32. A gel
negative HPV result was defined as a sample demonstrat-
ing the 268 bp β-Globin band but no 448 bp HPV band.
All HPV positive samples were applied to the reverse line
blot system according to Roche's protocol. Briefly, the
biotinylated PCR products were denatured for one hour at
room temperature and hybridized at 53°C in a shaking
water bath to strips containing probes for 27 HPV geno-
types. (high risk: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55,
56, 58, 59, 68, MM4, MM7, and MM9; low risk: 6, 11, 40,
42, 53, 54, 57, 66, and MM8). The strips were then
washed (1× SSPE-0.1% SDS) for 15 minutes in a 53°C
shaking water bath. SA-HRP was added to the strips and
shaken for 30 minutes at room temperature. This was fol-
lowed by two 10-minute washes. The strips were incu-
bated for 5 minutes, with shaking, in citrate buffer (0.1 M
Sodium Citrate). Color development was accomplished
via the addition of substrate 3,3',5,5'-tetramethylbenzi-
dine (TMB) with hydrogen peroxide. A blue precipitate
was observed at the probe locations that contained
hybridized PCR products. The reaction was stopped after
5 minutes with the addition of water and read immedi-
ately.
HPV-32 Dot Blot System
Samples that were gel-positive and line blot-negative were
then tested for HPV-32 via dot blot. This was performed
by re-amplifying samples with the MY09/11 primers
(table 1). The final concentrations in the 100 μL reaction
were 1× PCR Buffer II, 1.0 μM of each primer (MY09 and
MY11), 250 μM of each dNTP, 2 mM MgCl2, 7.5 U Ampl-
iTaq™ Gold and 5 μL of template DNA. The thermocycler
protocol was: 50°C for 2 minutes, 95°C for 9 minutes, 40
cycles of 95°C for 1 minute, 55°C for 1 minute, and 72°C
for 1 minute, extension at 72°C for 5 minutes, followed
by a 15°C hold. The 448 bp amplicons were detected and
visualized as detailed above.
MY09/11 amplicons (10 μL) from positive patients were
denatured for one hour in 100 μL of denaturation buffer
(1.5 M NaCl, 0.5 M NaOH, 0.025 M EDTA). This mixture
was applied to a nylon membrane (Micron Separations,
Inc.) that was pre-moistened in 6× SSPE using a Dot Blot
apparatus (Schleicher and Schuell, Keene, NH). The DNA
was then UV crosslinked to the membrane in a UV Strata-
linker 1800 (Stratagene, La Jolla, CA) using 120 mjoules
and dried overnight. The nylon membrane was put in pre-
hybridization buffer (0.1× SSPE-0.5% SDS) for one hour
at 65°C, followed by a one hour incubation at 65°C in
hybridization buffer (4× SSPE-0.5% SDS). The bioti-
nylated HPV-32 probe (5'-Biotin-AGG TGC TGT TAC CTT
AGC TTG-3') was mixed with hybridization buffer at a
concentration of 0.5 pmol/mL, and the membrane was
soaked in the probe solution for 30 minutes in a 53°C
shaking water bath. The remaining procedure is done
using the reverse line blot procedure as described above.
Specific Amplification of HPV-32 by PCR
The integrity of the stored DNA samples was verified via
PCR amplification and the detection of the 268 bp ampli-
con of the β-globin gene. Final concentrations in the 25
μL reactions were 1× PCR Buffer II, 0.25 μM of each
primer (GH20 and PC04; table 1), 200 μM of each dNTP,
4 mM MgCl2, 0.625 U AmpliTaq™ Gold and 5 μL of tem-
plate DNA. Thermocycling protocol was performed as fol-
lows: 50°C for 2 minutes; 95°C for 9 minutes, 40 cycles
of 95°C for 1 minute, 55°C for 10 seconds, and 72°C for
30 seconds, extension at 72°C for 5 minutes, followed by
a 15°C hold. The 268 bp amplicons were detected and vis-
ualized as described above.
The primer sequences for the HPV-32 specific PCR were 5'
GTG GCC GCC TAG TGA CAA C 3' (HPV-32 Det For) and
5' GAT GCC CAA CAG CCA AAA G 3' (HPV-32 Det Rev).
The final concentrations for the 25 μL HPV-32 Specific
PCR reaction were 1× PCR Buffer II, 0.5 μM of each
primer, 200 μM of each dNTP, 1.5 mM MgCl2, 0.625 U
AmpliTaq™ Gold and 5 μL of template. Thermocycling
was performed as follows: 95°C for 9 minutes; 40 cycles
of 95°C for 1 minute, 58.5°C for 10 seconds, and 70°C
for 30 seconds; extension at 70°C for 5 minutes, followed
by a 15°C hold. The 134 bp amplicons were detected and
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The primer sequences for the HPV-32 E6/E7 specific PCR
were 5' TAT AAC GGA CGG CAT TTC AGA TTC 3' (HPV-
32 E6E7 For) and 5' GTC ACT CCA CGC AGG CAC AC 3'
(HPV-32 E6E7 Rev). The final concentrations for the 25
μL HPV-32 E6E7 Specific PCR reaction were 1× PCR
Buffer II, 0.5 μM of each primer, 200 μM of each dNTP,
2.0 mM MgCl2, 0.625 U AmpliTaq™ Gold and 5 μL of
template. Thermocycling was performed as follows: 95°C
for 9 minutes; 40 cycles of 95°C for 1 minute, 58°C for 10
seconds, and 75°C for 30 seconds; extension at 75°C for
5 minutes, followed by a 15°C hold. The 382 bp ampli-
cons were detected and visualized as described above.
Contamination was controlled for all work by using bar-
rier pipet tips. Lab benches were bleached after each
extraction and prior to any PCR work. DNA extraction,
PCR setup, and the addition of template was performed in
separate rooms to minimize cross contamination. All
plasmid work was done in a separate room as well. Possi-
ble contamination in extractions and PCRs was moni-
tored through the inclusion of extraction controls for each
extraction and no template control that went through the
same mechanical manipulations as samples after every
third sample on all PCRs.
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